WebFeb 6, 2024 · This study is designed to evaluate the efficacy and safety of GB0139, a galectin-3 inhibitor, administered by dry powder inhalation over 52 weeks. GB0139, … WebNov 27, 2024 · Idiopathic pulmonary fibrosis (IPF) is a common and severe form of pulmonary fibrosis. Nintedanib, a triple angiokinase inhibitor, is approved for treating IPF. Galectin 3 (Gal-3) activates a variety of profibrotic processes. Currently, the Gal-3 inhibitor TD139 is being tested in phase II clinical trials.
Target inhibition of galectin-3 by inhaled TD139 in patients …
WebDrug DetailsGB0139 (formerly TD139) is a galectin-3 inhibitor administered by dry powder inhalation.Study PurposeThis is a randomized, double-blind, placebo-controlled phase … WebRationale: Idiopathic pulmonary fibrosis (IPF) is a chronic dysregulated response to alveolar epithelial injury with differentiation of epithelial cells and fibroblasts into matrix-secreting myofibroblasts resulting in lung scaring.The prognosis is poor and there are no effective therapies or reliable biomarkers. Galectin-3 is a β-galactoside binding lectin that is highly … qp bug\u0027s
Target inhibition of galectin-3 by inhaled TD139 in patients with ...
WebGalecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial) Galecto WebJun 10, 2024 · Galectins are β-galactoside-binding proteins. They participate in intracellular trafficking, cell adhesion, and cell–cell signaling. They play a pivotal role in physiological and pathological activities, such as, inflammation, immune response, and … WebFeb 1, 2024 · Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary ... domino\u0027s pizza ladysmith va